Mirabegron
178-CL-207
Phase 3 small_molecule active
Quick answer
Mirabegron for Neurogenic detrusor overactivity (NDO) is a Phase 3 program (small_molecule) at Astellas Pharma GmbH with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Astellas Pharma GmbH
- Indication
- Neurogenic detrusor overactivity (NDO)
- Phase
- Phase 3
- Modality
- small_molecule
- Status
- active